We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/2/2017 09:08 | Bought another 8k worth last couple days did not imagine getting them at this price again | leedslad001 | |
14/2/2017 17:18 | Strange trading lately, now 2 x 500k trades showing late....... | barrywhit | |
07/2/2017 18:12 | Someone bought a nice chunk today at a pretty premium - hence the retrace on the bid price.ODX appear to have a large team out in Dubai for the medlab series event. HTTp://www.medlabser | longshanks | |
03/2/2017 14:39 | ....are we on our way?The trading pattern has developed a very tight pennant over the last 3-6 months which mirror a larger pennant covering the last 3 years. We could easily see a break-out from here. | longshanks | |
02/2/2017 14:14 | Thanks for that Rivaldo, not that surprising though bearing in mind that L&G hold 12.88% of ODX and have been onboard for over 6 years now, they must be as keen as we all are to see a bit of share action :o) | hyperboreus | |
02/2/2017 13:42 | FYI, at Tuesday's Cenkos Growth Company Show, Richard Penny (senior fund manager at L&G UK Alpha Trust) noted ODX as one of his favoured investment ideas under the Medical Device category in his presentation. | rivaldo | |
31/1/2017 19:13 | a lot changing hands again..... | barrywhit | |
27/1/2017 17:21 | I am guessing that the 100k trade (just announce) filled at 17.63 is a buy. | longshanks | |
27/1/2017 16:12 | Just been quoted 17.785p to sell 80k, so it looks like they are hunting for shares... | barrywhit | |
27/1/2017 13:02 | I was quoted 17.6 to sell in quantity this morning so given it was at 8:45 I think it was a sell.I agree with dibs though; looks well bid | longshanks | |
27/1/2017 12:19 | I would think the 155k trade was a buy..... | barrywhit | |
27/1/2017 11:59 | I wonder if the delayed sell 155294@ 17.6 is the tale end of the offloading. Now that the IDH situation has been clarified it also frees our BoD, should they be in the mood, to fill their boots. | longshanks | |
27/1/2017 11:54 | Yep def barry. What's puzzling me is the bid is up and large trade 155k for 17.6 but no sign of any buys? Anyone got sight of L2? What's the order book look like? There must be a large one out there being filled? Sneller again? | dibs61 | |
27/1/2017 11:21 | Dibs, Thanks and yes I know the Enterprise grant was to help fund the expansion of the Allersys range which was a great help, but if IDH also help with the cost it will free up funds for the ongoing CD4 costs....just a thought.... | barrywhit | |
27/1/2017 10:52 | Barry - the RNS 2.8.2016 stated: "Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has secured a Scottish Enterprise research and development grant of £1.8 million. The R&D grant represents a significant contribution towards the total R&D project costs to fund the planned expansion of the Company's Allersys® range of reagent" So this will cover a significant portion of the total cost. Perhaps the remainder will be covered by internal resources or a small part of a future fundraising? | dibs61 | |
27/1/2017 09:21 | My concern is more working capital. They need cash to finance CD4 roll-out when it happens and whilst the payback will be rapid, cash flow will be a problem.Anyway, going by his twitter feed, the sales director is still travelling extensively to far-flung parts of the world so I guess cash is not yet that tight! | longshanks | |
27/1/2017 08:37 | Perhaps IDH will help fund the enlarged allergy tests as ODX were looking to increase from the 41 already CE marked to I think they stated 120..... as cash will be required for the expansion.... | barrywhit | |
27/1/2017 07:59 | ODX do need cash and I wouldn't be surprised if a fundraising happens if the discussions with iDH don't involve any upfront cash. I am sure the business can also support some debt now and as we are at a discount to NAV that may be a better option. | longshanks | |
27/1/2017 07:42 | Might it mean cash needed if no injection from elsewhere? It is a vote of confidence. | p1nkfish | |
27/1/2017 07:36 | So, when does the existing deal expire? Or what notice period is involved. If ODX don't have a distribution network, presumably one or more third parties need to be tasked with that. ODX just need to ensure they gain as much benefit as possible from the arrangement(s). | shanklin | |
27/1/2017 07:28 | Today's RNS confirming that IDH wants an "enlarged" distribution relationship with ODX is a vote of confidence in the company's products: There doesn't appear to be any froth at all in the share price from anyone expecting a multi-million pound sale of the allergy business, so I'd hope that no-one would be too disappointed. | rivaldo | |
27/1/2017 07:25 | Best of both worlds, increaed reach likely. | p1nkfish | |
27/1/2017 07:25 | So ODX plough the field, sow the seed, reap the crop, mill the corn and bake the bread. And now, having done little to help, IDH want a bigger slice of that bread.They should be able to extract a pretty penny from them for the privilege. | longshanks | |
24/1/2017 14:00 | Smart move longshanks imho | hyperboreus | |
24/1/2017 11:30 | Picked up all that were available at 17.2188 (37.5k). | longshanks |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions